Walgreens and Prime Therapeutics team up in new coordinated pharmacy model

On a relative basis, the stock has outperformed the S&P 500 by 0.39% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. Quarterly performance of the company shows optimistic momentum of 5.42% while its last one month trend is positive with 0.63%. Firm’s yearly sales growth for the past five year was 8.90%.

Walgreens Boots Alliance, Inc.’s short ratio is at 2.32 and the float short is at 1.19%.

On the company’s financial health, Walgreens Boots Alliance Inc reported $1.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 6, 2016. MDT market capitalization is 121.76B with 88000 employees.

The dividend will be paid on September 23, 2016, to shareholders of record as of the close of business on September 9, 2016. Company gross margin stands at 81.40% whereas its return on investment (ROI) is 12.50%. The ex-dividend date of this dividend is Wednesday, August 17th.

In related news, EVP Kathleen Wilson-Thompson sold 29,695 shares of Walgreens Boots Alliance stock in a transaction on Friday, July 8th. The latest trading activity of 4.12 Million shares is below its average volume of 5.51 Million shares. (WBA), have changed -0.07% and 80.93%, respectively. The investment firm sold 2,417 shares of WBA which is valued $194,883. The company’s institutional ownership is monitored at 61.4%. The disclosure for this sale can be found here.

Other Hedge Funds, Including, Modera Wealth Management sold out all of its stake in WBA during the most recent quarter. CapWealth Advisors LLC boosted its stake in Walgreens Boots Alliance by 30.0% in the first quarter. WBA’s profit will be $1.05 billion for 20.04 P/E if the $0.99 EPS becomes a reality. Stock’s weekly performance expressed down trend of -1.27%.

10/29/2015 – Walgreens Boots Alliance, Inc. had its “buy” rating reiterated by analysts at S&P Capital IQ.

Pharmacy Benefits managers negotiate deals on behalf of employers or government health programs (Medicaid and Medicare, for example), in an effort to help clients better coordinate their medical care and, more importantly, to manage drug costs. (WBA) today announced that it had agreed with AmerisourceBergen Corporation (ABC) to amend the second tranche of warrants held by Walgreens Boots Alliance to purchase AmerisourceBergen common stock, so as to permit the immediate exercise of these warrants.

Historically, if we look at price target revisions, three weeks ago Walgreens Boots Alliance Inc (NASDAQ:WBA)’s price target was revised on 08/02/16 by the analysts, however the bullish price estimates of the stock set at $103.00 while the bearish estimates kept at $79.00 over the next one year. The Company’s portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as global health and beauty product brands, including No7, Botanics, Liz Earle and Soap & Glory.